semaj83/ctmatch_classification huggingface dataset:
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 8.0-18.0,  Bipolar Disorder Depression Free of manic symptoms for at least 4 weeks. Must be treated with valproate or lithium (mood stabilizers) for at least 4 weeks. Meet for major depression and bipolar disorder (BP-I, BP-II, or BP-NOS). Not pregnant  Patients with schizophrenia, autism, schizoaffective disorder, organic mood disorder, obsessive-compulsive disorder, eating disorder, and psychosis. IQ less than 70. Significant chronic medical illness such as diabetes, epilepsy. Pregnancy. Substance abuse in last 3 months. Concurrent psychotherapy. Previous lack of response to adequate treatment with fluoxetine or other SSRI. Current use of psychoactive medication other than lithium or valproate
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Tobacco Use Disorder Smoke at least 10 cigarettes per day Report concern about cessation-related weight gain Motivated to quit smoking  Currently pregnant, lactating, or no medically approved method of contraception Major medical problem History of seizure disorder or head injury Current or historical psychosis or bipolar disorder History of alcohol or substance abuse within previous year Current or historical eating disorder Use of antidepressant medication, monoamine oxidase inhibitor or lithium with previous month Multiple Drug Allergies Current major depressive disorder
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 15.0-999.0,  Bipolar Disorder General current age 15 or older (Best Practice Pathway) or 18 years or older (Randomized Care Pathways) able to give informed consent for data to be harvested meet DSM-IV for Bipolar I Disorder, Bipolar II Disorder, Bipolar Disorder NOS, or Cyclothymic Disorder undergo a complete standard evaluation including clinical interview, self ratings, and laboratory studies meet with Clinical Specialist as scheduled able to complete all Study Registry Forms within 3 months of registration General  unwilling or unable to adhere to basic study requirements (i.e., complete rating forms, or attend scheduled evaluations) not competent to give informed consent in the opinion of the investigator (e.g., psychotic) Participants will be asked to remain in the study for up to five years so that the investigators can document and evaluate long-term treatment outcome. Participants will meet with their STEP-BD psychiatrist for periodic evaluations and/or treatment adjustments during the course of the study, fill out various self-rating forms, and when applicable, participate in psychotherapy. One of the psychotherapy options, Family-Focused Therapy, will require participants and their families to attend counseling sessions together. Overall, the estimated amount of time required from participants in the study is 2 to 4 hours per month
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Bipolar Disorder ARE NOT BEING FOR THIS STUDY FOR Patients must meet the following in order to participate in the study Male or female inpatients in need of treatment for severe bipolar depression 18-75 years of age Women of childbearing potential must be using an adequate form of contraception as defined by one of the following: 1) a barrier method and 2) oral contraceptives plus a barrier method (women who are on an OCP will be kept on it others must agree to use only a barrier method) DSM-IV diagnosis of bipolar depression I/II, severe, with or without psychotic features A current major depressive episode of at least 6 weeks' duration Score of greater than or equal to 18 on the first 17-item HAM-D at the prestudy visit and at the first baseline phase visit Score of 15 or greater on the HAM-D (17) at the end of the baseline period(s) (i.e., at randomization no more than 20% less than entry enrollment criteria)  FOR Patients will be excluded from the study if they meet any of the following Women who are pregnant, intending to become pregnant in the next month or breast-feeding Treatment with any of the following therapies within the specified interval prior to baseline: Fluoxetine weeks; Investigational compounds 4 weeks; MAOIs 1 week; Other antidepressants 1 week Contraindication or history of hypersensitivity to mifepristone as well as cortisol, and CRH Clinically significant organ system disease where mifepristone would be contraindicated or interfere with medical treatment Have evidence of any disorder that represents a contraindication to the use of mifepristone (such as adrenal disease or a condition requiring chronic corticosteroid administration) History of Addison's Disease, Cushing's Disease, insulin dependent diabetes, or other uncompensated endocrine conditions Evidence of infection, severe liver, respiratory, or renal disease
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Schizophrenia Psychotic Disorders Bipolar Disorder You must be between the ages of 18 and 65. If you have reached your 66th birthday, you will not be able to participate You must have been diagnosed with schizophrenia, schizoaffective disorder, schizophreniform disorder, or bipolar I disorder and be taking olanzapine You must be able to visit the doctor's office as scheduled for the next 4 months  You have a history of an illness that would cause weight loss or gain in the near future You have taken remoxipride within the past 6 months You are allergic to olanzapine or Anti-obesity Agent You have uncontrolled high blood pressure, congestive heart failure, or have had a stroke You have a serious medical illness, such as heart, liver, or kidney disease You are pregnant or breast feeding
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 16.0-999.0,  Bipolar Disorder Bipolar I or II Disorder Meet for rapid cycling, defined as four or more episodes over the past 12 months Meet for a major depressive episode  History of intolerability of lithium, divalproex, or lamotrigine
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 15.0-999.0,  Depression Score of 16 or higher on the Center for Epidemiological Studies Depression (CES-D) Scale Child who is 6 weeks to 30 months old Child who is enrolled in an Early Head Start program  Regular use of psychotropic medication Regular use of psychotherapy or drug/alcohol treatment
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Alzheimer Disease Patient is between the ages of 40 and 90 (inclusive) Patient will have a diagnosis of AD; the study will be confined to patients who are able to provide consent (pass a capacity assessment) The modified Hachinski Ischemia Score must be less than 4 Brain MRI performed within 15 months of enrollment must be compatible with the diagnosis of AD Patient and/or caregiver are willing to adhere to protocol requirements as evidenced by written, informed consent  Patients meeting any of the following during screening or during the study will not be enrolled or will be immediately excluded from the study, as appropriate Patient has a history of any medical condition that can reasonably be expected to subject the patient to unwarranted risk Patient has clinically significant laboratory abnormalities that would preclude administration of lithium and divalproex Patient is taking a prohibited concomitant medication. The following medications are forbidden for at least one month prior to the treatment phase (unless otherwise noted) and during the course of the study Any investigational drugs Anti-depressants (eligibility will be considered as long as dosage remains stable throughout the study) Anticonvulsants and other mood stabilizing drugs Treatment that may provoke lithium toxicity due to reduced renal clearance, including metronidazole, spectinomycin, tetracycline Treatment that may substantially increase steady-state plasma lithium levels resulting in lithium toxicity, including angiotensin-converting enzyme inhibitors, diuretics
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Cannabis Dependence Substance Withdrawal Syndrome DSM-IV diagnosis of cannabis dependence with at least a three-month history Seeking treatment for primary cannabis problem Withdrawal identified as barrier to abstinence  Other drug dependency (excluding nicotine) Client is breastfeeding or pregnant Client has contraindicated medical or psychiatric conditions Client currently taking other medications that may interact with lithium Known hypersensitivity / side effects with Lithium Currently receiving Lithium from another source Currently prescribed any antidepressant / mood stabilising / antipsychotic medication Currently receiving opioid pharmacotherapy
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 8.0-17.0,  Bipolar Disorder Attention Deficit Hyperactivity Disorder Age: 8-17 BD type I or II comorbid with ADHD Baseline score in the YMRS > or = 20  IQ < 70 Pharmacologic treatment in the last month Pregnancy or absence of a contraceptive method in fertile girls Diagnoses: pervasive development disorder, schizophrenia, drug abuse or dependency Risk of suicide or homicide Clinical condition that might interfere in the study Known sensibility to aripiprazole
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Bipolar Disorders Aged 18-65 Minimum two year history of depressive and hypomanic episodes Mood episodes occuring monthly Meet DSM-IV for Bipolar II Disorder (with exception of minimum 4 day period for hypomanic episodes)  Previous treatment with any antidepressant, mood stabilizer or neuroleptic medication History of psychotic symptoms during hypomanic or depressive episodes Current suicidal behaviours Current substantive illicit drug use or alcohol consumption Significant personality disorder Pregnancy or breastfeeding History of heart disease, liver disease, epilepsy or seizures
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 25.0-55.0,  Insomnia Primary Insomnia Psychophysiologic Insomnia Ages 25 a stable sleep/wake schedule with a preferred sleep phase between 10:00 p.m. and 8:00 a.m Patients with Primary Insomnia will meet diagnostic for Psychophysiologic Insomnia according to the International Classification of Sleep Disorders manual (ICSD) complaint of disturbed sleep must have the following characteristics: >30 minutes to fall asleep, and/or >30 minutes wake after sleep onset time, a total sleep time of no more than 6.5 hours (or a sleep efficiency of less than 85%), a problem frequency of >4 nights/ week and a problem duration >6 months  Unstable medical or psychiatric illness Use of medication that may cause insomnia or may be reduce the effectiveness of zolpidem (e.g. selective serotonin reuptake inhibitors(SSRI's), steroids, bronchodilators, calcium channel blockers, beta blockers, etc.) symptoms suggestive of sleep disorders other than insomnia polysomnographic data indicating sleep disorders other than insomnia Evidence of active illicit substance use or fitting for alcohol abuse or dependence inadequate language comprehension pregnancy first-degree relatives with bipolar disorder or schizophrenia
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Bipolar Disorder Panic Disorder Generalized Anxiety Disorder Subjects must be 18 years of age or older Subjects must have lifetime bipolar I, II, or NOS disorder as defined by DSM-IV criteria Subjects must have lifetime panic disorder or generalized anxiety disorder (GAD) as defined by DSM-IV (except clause “does not occur exclusively during a mood disorder” of Criterion F for GAD)  Subjects’ bipolar symptoms must be no more than moderately severe, defined as a CGI-BP < 4 Subjects’ anxiety symptoms must be at least moderately severe, defined as a CGI-S > 4 Subjects must not be receiving mood stabilizing, antidepressant, antipsychotic, or anxiolytic medication for > one week prior to baseline. Patients receiving fluoxetine or depot antipsychotics should be off these medications for > four weeks prior to baseline Subjects or their legally authorized representative must sign the Informed Consent Document after the nature of the trial has been fully explained If female, subjects must be: postmenopausal, surgically incapable of childbearing, or practicing medically acceptable effective method(s) of contraception (e.g., hormonal methods, double barrier methods, intrauterine device) for at least one month prior to study entry and throughout the study  Subjects who do not have lifetime bipolar disorder by DSM-IV-TR criteria Subjects who do not have lifetime panic disorder or generalized anxiety disorder by DSM-IV-TR criteria Subjects who are receiving treatment with an antimanic or mood stabilizing medication (lithium, valproate, carbamazepine, or an antipsychotic), and in the investigators’ judgment, require ongoing treatment with that medication Subjects whose bipolar symptoms are presently more than moderately severe (CGI-BP > 5) Subjects whose anxiety symptoms are presently less than moderately severe (CGI < 3) Subjects with clinically significant suicidal or homicidal ideation Subjects with current psychotic symptoms Subjects with a current DSM-IV Axis I diagnosis of delirium, dementia, amnesia, or other cognitive disorders; a DSM-IV diagnosis of a substance dependence disorder within the past six months; a lifetime DSM-IV psychotic disorder (e.g., schizophrenia or schizoaffective disorder) Subjects with serious general medical illnesses including hepatic, renal, respiratory, cardiovascular, endocrine, neurologic, or hematologic disease as determined by the clinical judgment of the clinical investigator. Subjects with hypo or hyperthyroidism unless stabilized on thyroid replacement > 3 months
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Depression males or females age 18 to 65 years, DSM-IV episode of Major Depression non-psychotic, ≥14 score on the 17-item HRSD, adequate trial with two antidepressants (see definition above of 'adequate trial'), ability to receive and give informed consent, if patients are of child-bearing potential (male or female), use of an effective contraceptive is required for at least one month prior to the screening Visit and documentation of a negative pregnancy (female) test upon entry into the study  bipolar or psychotic depression, overt personality disorder, currently suicidal or a history of suicide attempt in the previous 6 months, current substance abuse or history of substance abuse in the previous 12 months, history of hypersensitivity to aripiprazole, treatment with antipsychotic medications in the previous 3 months, serious or unstable medical disorders which in and amongst themselves may lend to morbidity or mortality during study, any medical illness with relative contraindication for aripiprazole use, starting or terminating psychotherapy during the previous 12 weeks, ECT treatment in the previous 3 months, pregnancy or planning pregnancy, history of severe head injury with sequelae, comorbid anxiety condition which has been focus of clinical attention in previous 6 months (remitted GAD, OCD, Panic, Social Anxiety, PTSD may be allowed)
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 20.0-50.0,  Sleep Disorders Physically healthy Meets DSM-IV for primary insomnia For subjects interested in PET study only: right-handedness  Currently taking antidepressants, antianxiety medications or medications for sleep disorders Currently experiencing symptoms of psychiatric disorders such as major depressive disorder, bipolar disorder, generalized anxiety disorder Significant or unstable acute or chronic medical conditions, such as seizure disorder, tumor, liver disease, active peptic ulcer disease, arthritis, irritable bowel disease Meets DSM-IV for sleep apnea or periodic limb movement disorder